Medical Developments International makes Penthrox, the inhaled methoxyflurane analgesic known as the 'green whistle', widely used for fast pain relief in emergency and hospital settings, alongside a respiratory-products business. Penthrox is well established in Australia and a growing number of international markets, and its expansion — including toward the large United States market — is the core of the company's growth story.

In its third-quarter FY26 update, to 31 March 2026, Medical Developments (ASX:MVP) reported total Revenue up 19% to A$10.5 million, with pain-management revenue — driven primarily by Penthrox — up 47% to A$8.4 million, and it generated positive Operating Cash Flow of A$2.5 million in the quarter. Penthrox has secured approval in 12 European markets, with United Kingdom approval anticipated and expanded paediatric use, and the company held A$18.7 million in cash.

The strong Penthrox growth and the return to positive operating cash flow are the key developments, offsetting softer Demand in the respiratory division.

What Could Drive the Shares Next?

Catalysts include continued Penthrox revenue growth, new market approvals — including the anticipated United Kingdom approval — progress toward the United States market, paediatric and indication expansion, and sustained positive cash flow. A major new market approval would be the most powerful potential driver.

Evidence that Penthrox can keep expanding geographically while the Business generates cash would support a re-rating.

Risks Investors Should Watch

The company is heavily dependent on a single product, Penthrox, so regulatory and commercial outcomes for it carry outsized weight. Entering large new markets such as the United States involves regulatory hurdles and uncertainty.

Softer respiratory demand, competition, and the pace of approvals and market expansion are additional considerations.

Investor Takeaway

Medical Developments International grew third-quarter FY26 revenue 19% on a 47% jump in Penthrox-led pain-management revenue and returned to positive operating cash flow. Whether the next catalyst sparks a re-rating depends on Penthrox's continued expansion and new market approvals. Penthrox growth, market approvals and cash flow are the things to watch.